Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Teucrium Soybean Fund (SOYB) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Teucrium Soybean FundTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Teucrium Soybean Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Teucrium Soybean Fund trades at $25.05. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYSOYB
Market Cap
$29.60B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$491.22$26.28
52-Week Low
$205.48$21.46
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Teucrium Soybean Fund

SOYB trades at $25.24, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights agricultural sector tailwinds from China's crop purchase pledge, though geopolitical risks from Middle East tensions pose headwinds.

The outlook hinges on sector-specific catalysts like export demand, but absent financial data obscures valuation. Risks include commodity volatility and geopolitical spillovers. Investors require updated SEC filings to assess profitability and growth prospects amid mixed technical signals.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Teucrium Soybean Fund

SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.

Read more on SOYB